Hotgen(SH:688068) Zhi Tong Cai Jing·2025-10-22 08:17Core Viewpoint - The company reported positive preliminary results from the Phase Ib clinical trial of its innovative drug SGC001, developed by its affiliate Beijing ShunJing Biopharmaceutical Technology Co., Ltd [1] Group 1: Clinical Trial Results - The preliminary efficacy results indicate that SGC001 shows a trend of effectiveness in myocardial protection for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) [1] - In the 600mg and 900mg dosage groups, SGC001 demonstrated a reduction in myocardial infarction area percentage (IS%) compared to the placebo group, with median reductions of 20.5% and 38.1% respectively [1] - The time required for high-sensitivity troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels was shorter in the treatment groups compared to the placebo group [1]